Results 251 to 260 of about 436,080 (311)

A retrospective observational study of clinical presentation and management outcomes in patients with paroxysmal supraventricular tachycardia at a tertiary center in Bahrain. [PDF]

Front Cardiovasc Med
Zeidan O, Alohaly A, Zayer A, Jaragh N, Alqayem M, Ziedan A, Fredericks S, Assar W.   +7 more
europepmc   +1 more source

Inosine‐Triphosphate‐Pyrophosphatase Activity as a Potential Predictor of Methotrexate Remission in Juvenile Idiopathic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Methotrexate (MTX) is the first‐line therapy for juvenile idiopathic arthritis (JIA), but up to 40% of patients do not respond to it. Low inosine triphosphate pyrophosphatase (ITPA) activity has been associated with reduced clinical remission. We investigated the role and underlying mechanisms of ITPA in vitro. Methods ITPA enzymatic activity
Sofia Sindici Forgiarini, Marianna Lucafò, Debora Curci, Davide Selvestrel, Valentina Moressa, Sofia Pagarin, Barbara Bellich, Martina Franzin, Alberto Tommasini, Mara L. Becker, Laura B. Ramsey, Susan D. Thompson, Carl D. Langefeld, Federica Corba, Edoardo Marrani, Gabriele Simonini, Gabriele Stocco, Giuliana Decorti, Andrea Taddio, Serena Pastore   +19 more
wiley   +1 more source

Restoring adenosine balance in axial spondyloarthritis: a stage-specific framework for immune and structural modulation. [PDF]

Front Immunol
Tavasolian F, Ravarian B, Lim M, Inman RD.   +3 more
europepmc   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Adenosine Pathway Activation Defines Genetically Linked Immunosuppressive Subtypes in Solid Tumor Brain Metastases. [PDF]

Cancers (Basel)
Bauer A, Arndt A, Reichenbach L, Gebauer N, Müller M, Neumann C, Schulz C, Steinestel K, Heller R, Chteinberg E, Busch H, Riecke A, Künstner A, Witte H.   +13 more
europepmc   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, Accepted Article.
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz, Seza Ozen, Hacer N. Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet E. Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet O. Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Engineering an AIEgen-based platform integrating CRISPR/Cas9 to remodel the tumor microenvironment and reinforce photo-immunotherapy against glioblastom. [PDF]

Signal Transduct Target Ther
Luo G, Ma F, Yang Y, Yang C, Li X, Xie J, Xiong K, Chen P, Ma K, Zhao Z, Tang BZ, Duo Y.   +11 more
europepmc   +1 more source

Prolotherapy in the Treatment of Knee Osteoarthritis: How to Perform

Arthroscopy Techniques, EarlyView.
Abstract The conservative treatment of knee osteoarthritis is a challenge; since it has no cure, many patients do not want or cannot undergo surgical procedures. Among the various options, we have injectable therapies, especially the so‐called “regenerative,” such as the use of hyaluronic acid, orthobiologicals, and prolotherapy. In the latter, its use
José L. Rocha de Faria, Fabiana Alves C. Menegassi, Sandra T. N. Minamoto, Guilherme Blois V. Pereira, Fábio Henrique P. Videira, Diego G. Severgnine, Caio Gomes de Lima, José Paulo G. Aramburu Filho, Geraldo da R. Motta, João Antônio M. Guimarães, Ronaldo José Faria C. do Amaral, Bianca Gutfilen, Sergio Augusto L. de Souza, Zartur José B. Menegassi   +13 more
wiley   +1 more source

Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies. [PDF]

Sci Rep
Li J, Goda AE, Enriquez-Vera D, Fujii S, Harazono S, Araujo JM, Nishikoba N, Velarde S, Namli AZ, Huamani Ortiz AJ, Nakahata S.   +10 more
europepmc   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source